Results 11 to 20 of about 219,582 (315)

Sortilin as a Regulator of Lipoprotein Metabolism [PDF]

Current Atherosclerosis Reports, 2012
Elevated low-density lipoprotein cholesterol (LDL-C) is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD) and myocardial infarction (MI). Much of the insight into LDL metabolism has been gained through the study of Mendelian disorders of lipid metabolism.
Strong, Alanna, Rader, Daniel J.
openaire   +2 more sources

Lipoprotein(a) Modulates Carotid Atherosclerosis in Metabolic Syndrome

Frontiers in Molecular Biosciences, 2022
Background and Aim: High lipoprotein(a) [Lp(a)] is a well-established cardiovascular (CV) risk factor, but the effect of mildly elevated Lp(a) on CV health is largely unknown. Our aim was to evaluate if Lp(a) is associated with the severity of carotid atherosclerosis (CA) in the specific subset of metabolic syndrome (MetS).Patients and Methods ...
Anna Laura Cremonini, Anna Laura Cremonini, Andrea Pasta, Federico Carbone, Federico Carbone, Luca Visconti, Matteo Casula, Edoardo Elia, Aldo Bonaventura, Aldo Bonaventura, Luca Liberale, Luca Liberale, Maria Bertolotto, Nathan Artom, Silvia Minetti, Paola Contini, Paola Contini, Daniela Verzola, Roberto Pontremoli, Roberto Pontremoli, Francesca Viazzi, Francesca Viazzi, Giorgio Luciano Viviani, Stefano Bertolini, Aldo Pende, Aldo Pende, Fabrizio Montecucco, Fabrizio Montecucco, Livia Pisciotta, Livia Pisciotta   +29 more
openaire   +3 more sources

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

Journal of Lipid Research, 2012
We carried out a genome-wide association study (GWAS) of LDL-c response to statin using data from participants in the Collaborative Atorvastatin Diabetes Study (CARDS; n = 1,156), the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT; n = 895), and the ...
Harshal A. Deshmukh, Helen M. Colhoun, Toby Johnson, Paul M. McKeigue, D. John Betteridge, Paul N. Durrington, John H. Fuller, Shona Livingstone, Valentine Charlton-Menys, Andrew Neil, Neil Poulter, Peter Sever, Denis C. Shields, Alice V. Stanton, Aurobindo Chatterjee, Craig Hyde, Roberto A. Calle, David A. DeMicco, Stella Trompet, Iris Postmus, Ian Ford, J. Wouter Jukema, Mark Caulfield, Graham A. Hitman   +23 more
doaj   +1 more source

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects

Frontiers in Physiology, 2021
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a convertase enzyme mostly produced by the liver. It is a key regulator of LDL metabolism because of its ability to enhance degradation of the LDL receptor.
Qidi Ying, Dick C. Chan, Gerald F. Watts, Gerald F. Watts   +3 more
doaj   +1 more source

Hepatic lipoprotein and cholesterol metabolism. Report of a conference

Journal of Lipid Research, 1988
R A Davis
doaj   +3 more sources

A computational model for the analysis of lipoprotein distributions in the mouse: translating FPLC profiles to lipoprotein metabolism.

PLoS Computational Biology, 2014
Disturbances of lipoprotein metabolism are recognized as indicators of cardiometabolic disease risk. Lipoprotein size and composition, measured in a lipoprotein profile, are considered to be disease risk markers.
Fianne L P Sips, Christian A Tiemann, Maaike H Oosterveer, Albert K Groen, Peter A J Hilbers, Natal A W van Riel   +5 more
doaj   +1 more source

Lipoprotein(a) metabolism: Potential sites for therapeutic targets [PDF]

Metabolism, 2013
Lipoprotein(a) [Lp(a)] resembles low-density lipoprotein (LDL), with an LDL lipid core and apolipoprotein B (apoB), but contains a unique apolipoprotein, apo(a). Elevated Lp(a) is an independent risk factor for coronary and peripheral vascular diseases. The size and concentration of plasma Lp(a) are related to the synthetic rate, not the catabolic rate,
Jane, Hoover-Plow, Menggui, Huang
openaire   +2 more sources

Plasma lipoproteins: apolipoprotein structure and function.

Journal of Lipid Research, 1984
Plasma lipoprotein metabolism is regulated and controlled by the specific apolipoprotein (apo-) constituents of the various lipoprotein classes. The major apolipoproteins include apoE, apoB, apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, and apoC-III ...
R W Mahley, T L Innerarity, S C Rall, Jr, K H Weisgraber   +3 more
doaj   +1 more source

Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation. [PDF]

PLoS ONE, 2014
Dietary medium chain fatty acids (MCFA) and linoleic acid follow different metabolic routes, and linoleic acid activates PPAR receptors. Both these mechanisms may modify lipoprotein and fatty acid metabolism after dietary intervention.
Daniël B van Schalkwijk, Wilrike J Pasman, Henk F J Hendriks, Elwin R Verheij, Carina M Rubingh, Kees van Bochove, Wouter H J Vaes, Martin Adiels, Andreas P Freidig, Albert A de Graaf   +9 more
doaj   +1 more source

ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36

Journal of Lipid Research, 2004
The class B scavenger receptors SR-BI and CD36 exhibit a broad ligand binding specificity. SR-BI is well characterized as a HDL receptor that mediates selective cholesteryl ester uptake from HDL.
Maria C. de Beer, Lawrence W. Castellani, Lei Cai, Arnold J. Stromberg, Frederick C. de Beer, Deneys R. van der Westhuyzen   +5 more
doaj   +1 more source